142 related articles for article (PubMed ID: 8033751)
61. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1990; 26(4):278-82. PubMed ID: 2369792
[TBL] [Abstract][Full Text] [Related]
62. Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
Makimoto G; Ichihara E; Hotta K; Ninomiya K; Oze I; Minami D; Ninomiya T; Kubo T; Ohashi K; Tabata M; Maeda Y; Kiura K
Acta Med Okayama; 2018 Jun; 72(3):319-323. PubMed ID: 29926012
[TBL] [Abstract][Full Text] [Related]
63. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
Morgan KP; Buie LW; Savage SW
Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
[TBL] [Abstract][Full Text] [Related]
64. Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism.
Levi F; Hrushesky WJ; Borch RF; Pleasants ME; Kennedy BJ; Halberg F
Cancer Treat Rep; 1982 Nov; 66(11):1933-8. PubMed ID: 6890406
[TBL] [Abstract][Full Text] [Related]
65. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis.
Gouyette A; Lemoine R; Adhemar JP; Kleinknecht D; Man NK; Droz JP; Macquet JP
Cancer Treat Rep; 1981; 65(7-8):665-8. PubMed ID: 7195773
[TBL] [Abstract][Full Text] [Related]
66. Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics.
Dumas M; d'Athis P; de Gislain C; Lautissier JL; Autissier N; Escousse A; Guerrin J
Eur J Drug Metab Pharmacokinet; 1987; 12(3):203-6. PubMed ID: 3436343
[TBL] [Abstract][Full Text] [Related]
67. Renal handling of cis-diamminedichloroplatinum(II).
Jacobs C; Kalman SM; Tretton M; Weiner MW
Cancer Treat Rep; 1980; 64(12):1223-6. PubMed ID: 7193518
[TBL] [Abstract][Full Text] [Related]
68. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.
Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J
Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556
[TBL] [Abstract][Full Text] [Related]
69. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
70. Phase I/II trials of WR-2721 and cis-platinum.
Glover D; Glick JH; Weiler C; Fox K; Turrisi A; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
[TBL] [Abstract][Full Text] [Related]
71. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
72. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
73. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
74. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial.
Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N
BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529
[TBL] [Abstract][Full Text] [Related]
75. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
76. 131I-Orthoiodohippurate clearance in the detection of cisplatin nephrotoxicity.
Hengst W; Wieler H; Rabs U; Bürger RA
Nuklearmedizin; 1985 Jun; 24(3):104-6. PubMed ID: 4059060
[TBL] [Abstract][Full Text] [Related]
77. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.
Muraki K; Koyama R; Honma Y; Yagishita S; Shukuya T; Ohashi R; Takahashi F; Kido K; Iwakami S; Sasaki S; Iwase A; Takahashi K
J Thorac Dis; 2012 Dec; 4(6):562-8. PubMed ID: 23205279
[TBL] [Abstract][Full Text] [Related]
78. [Administration of high doses of cisplatin in 20-minute infusions].
Cirera L; Gay M; Tomé T; Martí M; Huguet J; Plá R
Rev Clin Esp; 1988 Mar; 182(4):192-5. PubMed ID: 3137644
[No Abstract] [Full Text] [Related]
79. Lack of age-dependent cisplatin nephrotoxicity.
Hrushesky WJ; Shimp W; Kennedy BJ
Am J Med; 1984 Apr; 76(4):579-84. PubMed ID: 6538750
[TBL] [Abstract][Full Text] [Related]
80. A study of the protective effect of chloride salts on cisplatin nephrotoxicity.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1985 Jul; 34(13):2363-9. PubMed ID: 4040367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
